Michael J. Kuchenreuther, PhD

Immuno-oncology drugs are demonstrating patient benefits, but growing resistance to the high cost has implications for patients, market access, and manufacturers.

The author provides an overview of the key aspects of the current Canadian pharmaceutical market.

The authors look at key factors driving the risk-sharing agreements that have been implemented to reduce drug expenditures across Europe.

China’s emergence as a significant commercial market is forcing manufacturers to re-evaluate their overall business model.

With the French pricing and reimbursement policies becoming increasingly stringent, pharmaceutical manufacturers must adapt their drug development and commercial strategies if they want to secure premium pricing for their new products.

Bio/pharmaceutical manufacturers in the UK face challenges in proving that their drugs are worth the price.

The authors take a look at some of the recent developments in the German pharmaceutical market.

The authors take a look at some of the recent developments in the German pharmaceutical market.

Data analytic strategies can help companies capitalize on personalized medicine.

An established drug-manufacturing base with quality and safety issues, and patent protection and price capping concerns complicate efforts to do business in India.

Biopharma companies should not overlook India's growing market.

Israel's diverse population, high-quality healthcare system, and resilience to global financial stress make it a strong partner for R&D, clinical research, and market growth.